Kensey Nash Announces Commencement of Carotid Pivotal Trial for TriActiv ProGuard System
14th Nov 2006, 14:39 GMT
Kensey Nash Corp has commenced enrollment of a 300 to 400 patient pivotal study for its TriActiv ProGuard Embolic Protection System in carotid stenting procedures.
Kensey Nash Announces Commencement of Carotid Pivotal Trial for TriActiv ProGuard System related news:
- Kensey Nash Announces Commencement of Carotid Pivotal Trial for TriActiv ProGuard System — PR Newswire: All Releases
- Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma — Bio-Technology News from StratCenter.com
- Favrille Announces Interim Analysis Of Secondary Endpoint From Pivotal Phase 3 Clinical Trial Of FavId Following Rituxan — Health News from Medical News Today
- OTSP: Study to Be Published in JAMA: Diabetes Drug ACTOS(R) (pioglitazone HCl) Halted Progression of Key Marker for Atherosclerosis; Improvements Indicated by Carotid Intima-Media Thickness (CIMT) — Market Wire - Medical and Healthcare
- Bitrix Site Manager Vitrual Lab — PR.com Press Releases
- Stull, Stull & Brody Announces Commencement of Lawsuit Against Actel Corporation for the Back-Dating of Stock Option Grants -- ACTL — ArriveNet : Press Releases
- RB Nash gets four touches — NFL Player News : CBS SportsLine.com
- New data show ACTOS (pioglitazone HCl) halted progression of atherosclerosis as indicated by CIMT — EurekAlert! - Medicine and Health
- Amber Alert issued for missing Nash County 2-year-old — www.heraldsun.com
- Takeda Pharmaceuticals North America: New Data Show ACTOS(R) (pioglitazone HCl) Halted Progression of Atherosclerosis as Indicated by CIMT in Patients With Type 2 Diabetes — Market Wire - Medical and Healthcare
Latest news from Neurology News from StratCenter.com:
- Alzheimer's Foundation of America to Hold Nat'l Memory Screening Day
- Neurologix Announces Q3 Results
- New Study Finds Everyday Activities Trigger Smoking Cravings
- Neurobiological Technologies Review Issued by Scimitar Equity Research
- AQA Adopts Additional Standard Quality Measures for Practitioners in 25 Surgical and Medical Specialties
- StemCells' product transplanted in early clinical trial
- Acorda Therapeutics Added to NASDAQ Biotech Index
- StemCells Begins Study on Rare Disease
- StemCells Announces 1st Human Neural Stem Cell Transplant
- Vanda Pharmaceuticals' VEC-162 Demonstrates Positive Results in a Phase III Transient Insomnia Clinical Trial